Table 2.

Reasons for discontinuation by responder category in STRIDE and PACE

Reason	Total	Responders* After First Application	Responders* After Second Application	Responders* After Third Application	Others†
STRIDE	N = 306	n = 60	n = 33	n = 11	n = 202
Adverse event	11 (3.6)	2 (3.3)	0	1 (9.1)	8 (4.0)
Lack of efficacy	54 (17.6)	4 (6.7)	2 (6.1)	1 (9.1)	47 (23.3)
Protocol violation	6 (2.0)	1 (1.7)	0	0	5 (2.5)
Lost to follow-up	17 (5.6)	1 (1.7)	2 (6.1)	1 (9.1)	13 (6.4)
Withdrawal of consent	33 (10.8)	3 (5.0)	1 (3.0)	0	29 (14.4)
Other	9 (2.9)	0	0	0	9 (4.5)
PACE	N = 313	n = 96	n = 68	n = 43	n = 106
Adverse event	15 (4.8)	3 (3.1)	3 (4.4)	0	9 (8.5)
Lack of efficacy	4 (1.3)	2 (2.1)	0	0	2 (1.9)
Protocol violation	4 (1.3)	0	0	0	4 (3.8)
Lost to follow-up	3 (1.0)	0	1 (1.5)	0	2 (1.9)
Withdrawal of consent	25 (8.0)	4 (4.2)	2 (2.9)	0	19 (17.9)
Other	2 (0.6)	2 (2.1)	0	0	0

All data are n (%).

^*Response was defined as ≥30% reduction from baseline in pain intensity, assessed with the BPI.

^†Includes nonresponders to first or second application who were not offered subsequent applications, as well as nonresponders to third application.